Skip to main content
. 2018 Apr 15;10(2):50. doi: 10.3390/pharmaceutics10020050

Table 1.

IC50 values for the formulation in Daudi and Jurkat cells.

Study Duration 24 h 48 h
Formulation Type Free Drug LCLA LCCTLA Free Drug LCLA LCCTLA
Cancer Cell Type
Daudi 0.243 0.481 1.443 0.199 0.101 0.114
Jurkat 1.054 2.046 4.608* 0.509 0.238 0.438

LCLA: Untargeted long circulating liposomal AD 198; LCCTLA: Long circulating CD22 targeted liposomal AD 198.